NanoViricides, Inc. — Form 10-Q Summary
Period clarification: The request metadata says “2016 Q3,” but this filing reports the quarter and nine months ended March 31, 2017, compared with the same periods in 2016. The fiscal year ends June 30. All amounts below are U.S. dollars.
Business context and reporting period
NanoViricides is a development-stage antiviral biotechnology company. It reported no product revenue and has not commercialized a product. Its candidates remain in preclinical or advanced preclinical development. Management’s priority is topical herpes-virus programs, particularly a shingles treatment, alongside injectable FluCide for severe influenza.
Financial results and liquidity
| Metric | Three months ended March 31, 2017 | Nine months ended March 31, 2017 | Comparable 2016 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.56 million | $4.27 million | $1.07 million; $3.43 million |
| General and administrative expense | $1.06 million | $3.08 million | $0.98 million; $2.94 million |
| Operating loss | $2.62 million | $7.35 million | $2.05 million; $6.36 million |
| Net loss | $3.14 million | $7.75 million | $4.99 million; $9.07 million |
| Basic and diluted loss per share | $0.05 | $0.13 | $0.09; $0.16 |
The comparable-period figures in the table are shown in quarter; nine-month order. With no revenue, commercial margins are not meaningful. Research and development spending was the principal operating cost.
- Cash and cash equivalents: $16.16 million at March 31, 2017, down from $24.16 million at June 30, 2016.
- Cash flow: $6.89 million used in operating activities over nine months, versus $5.45 million in the prior-year period; $0.12 million used for property and equipment and $1.00 million paid toward Series B debentures. Ending cash declined by $8.01 million.
- Liquidity and liabilities: Current assets were $16.74 million and current liabilities $0.33 million. Total liabilities were $6.17 million, including $5.84 million of long-term liabilities. The Series C debenture has $5.00 million principal and a $3.73 million net carrying value.
- Equity and accumulated losses: Stockholders’ equity was $22.41 million; accumulated deficit was $72.57 million. Common shares outstanding increased from 58.18 million at June 30, 2016 to 63.07 million at March 31, 2017.
Material changes versus the prior comparable period
- Nine-month operating expenses increased $0.99 million, primarily reflecting higher research and development payroll, lab supplies, and materials.
- Nine-month net loss narrowed by $1.33 million, despite the higher operating loss. A favorable $1.68 million change in derivative fair value, compared with a $0.92 million loss in 2016, contributed significantly; this item is non-cash.
- The Series B debentures matured in January 2017. In February, holders converted $5.00 million principal and $27,178 accrued interest into common shares; the company paid the remaining $1.00 million principal in cash. It recorded a $332,524 non-cash debt-extinguishment loss.
- The company issued 4.34 million common shares for the Series B principal conversion, in addition to shares issued for interest, compensation, and services.
Outlook, commentary, and risks
- Management said available cash should fund operations for more than one year at the then-current expenditure rate and believed it could fund safety/toxicology work, an IND or comparable filing, and at least Phase I—and possibly Phase IIa—trials for at least one candidate. This is management’s estimate, not a guarantee.
- Management identified shingles topical treatment and injectable FluCide as late-preclinical or IND-enabling priorities. In an April 26, 2017 update cited in the filing, the company said it was nearing selection of a shingles candidate, with verification and selection work still underway.
- Development timelines and costs are uncertain and depend on study outcomes, manufacturing scale-up, raw-material availability, collaborators, and regulatory requirements. Management noted that delays or higher-than-expected costs could require reprioritizing programs or raising additional funds.
- The company has no revenue, expects losses to continue, and has an accumulated deficit. It depends on future financing, external collaborators and service providers, and its exclusive TheraCour license; loss of licensed rights could delay or increase the cost of development.
- The $5.00 million Series C debenture is owed to a director. The filing also reports related-party development fees paid to TheraCour of $2.48 million for the nine months and $370,187 in prepaid related-party expenses at period end.
- Potential dilution includes 6.66 million outstanding warrants and up to 15.19 million common shares contingently issuable upon a change of control for Series A preferred stock. The Series C debenture also has conversion and interest-payment provisions tied to common shares.
- The filing reported no pending or threatened legal proceedings known to the company, no off-balance-sheet arrangements, and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the reporting period: the filing is for the quarter ended March 31, 2017, notwithstanding the request’s “2016 Q3” label.
- Track cash burn against management’s stated runway and the estimated costs and timing of IND-enabling studies and clinical trials.
- Verify progress and reproducibility of shingles-candidate studies, manufacturing scale-up, and any subsequent regulatory filings or trial starts.
- Review the Series C debenture’s maturity, interest and conversion terms, the director relationship, and the company’s ability to meet obligations.
- Assess potential dilution from share-based compensation, warrants, debenture provisions, and contingent Series A preferred conversions.
- Distinguish operating performance from non-cash derivative valuation changes when interpreting reported net loss.